Executive Summary
Publicis Groupe S.A. secures stable revenue via subsidiary Plowshare Group's $374M CDC tobacco education contract (potential $498M with options), with $275M already outlayed through 2026-03-30. This Time & Materials award under full competition bolsters ad agency financials amid public health spending. Risks center on unspent obligations and audits; opportunities lie in $124M options and follow-ons.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from March 29, 2026.
Investment Signals (1)
- $374M CDC revenue stream through 2026 (HIGH)▲
Plowshare Group (Publicis subsidiary) has $275M outlayed of $374M obligated, providing multi-year stability in NAICS 541810 advertising.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Time & Materials contract vulnerable to government audits on hours/rates; only $275M of $374M outlayed.
- Regulatory [HIGH RISK]▼
Extended term to 2026-03-30 faces funding cuts or renewal uncertainty in HHS/CDC budgets.
Opportunities (2)
- ◆
$124M unexercised options ($498M total potential minus $374M obligated).
- ◆
Potential follow-on work in CDC tobacco campaigns post-2026.
Sector Themes (1)
- ◆
Large $374M T&M delivery order to ad agency signals sustained public health campaign spending through 2026.
Watch List (2)
- 👁
{"entity"=>"Publicis Groupe S.A.", "reason"=>"Contract represents material revenue; $99M remaining obligation + options could lift earnings.", "trigger"=>"Outlay acceleration to >$350M or option exercises"}
- 👁
{"entity"=>"CDC National Tobacco Education Campaign", "reason"=>"End-of-term in 2026-03-30 may prompt renewals or cuts.", "trigger"=>"Budget notices or new solicitations"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals